Mini eye implant aims to lower pressure in stubborn glaucoma

NCT ID NCT06591117

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests a small device called the Vizio Aqueous Microshunt, which is implanted in the eye to help drain fluid and reduce pressure in people with refractory glaucoma — a type that hasn't improved with standard treatments or prior surgeries. The trial will measure whether the implant lowers eye pressure by at least 20% after one year and whether it reduces the need for pressure-lowering eye drops. It also closely tracks any side effects or complications from the device or the implantation procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Vizio Aqueous Microshunt (a tiny implant placed in the eye to drain fluid and lower pressure)
What this could lead to
If it works, this implant could offer a new option for people with glaucoma that hasn't responded to other treatments, potentially reducing the need for daily eye drops.
What could go wrong
This is an early feasibility study with only 50 participants, so results may not apply to everyone. Risks include infection, implant failure, or the need for additional surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY GLAUCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Centro de Diabetes Ocular El Dios de Israel, S.A

    RECRUITING

    Colonia Escalón, San Salvadore, El Salvador

    Contact Phone: •••-•••-•••• Email: •••••@•••••